IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
104 hedge funds and large institutions have $1.36B invested in IGM Biosciences in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 23 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
57% more call options, than puts
Call options by funds: $4.54M | Put options by funds: $2.89M
19% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 32
2% less capital invested
Capital invested by funds: $1.38B → $1.36B (-$24.2M)
5% less funds holding
Funds holding: 109 → 104 (-5)
6.79% less ownership
Funds ownership: 70.61% → 63.83% (-6.8%)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$23.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.1M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$6.2M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$5.19M |
| 5 |
BC
Bruce & Co
Chicago,
Illinois
|
+$4.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$75.4M |
| 2 |
Goldman Sachs
New York
|
-$23.5M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$22.5M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$20.6M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$18.2M |
IGMS Hedge Fund Activity: Q2 2021 in Review
104 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q2 2021, worth a combined $1.36B — down 1.8% from $1.38B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of IGMS and 18 opened new positions — a net loss of 5 holders — while 32 trimmed existing stakes and 38 added.
The largest buyer was Woodline Partners, adding an estimated $23.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $75.4M sold.
- 104 institutional investors held IGM Biosciences (IGMS) as of Q2 2021, down from 109 in Q1 2021.
- Funds reported $1.36B of IGM Biosciences stock for Q2 2021, down 1.8% quarter-over-quarter.
- 18 funds opened new IGM Biosciences positions in Q2 2021 and 23 closed out, a net change of -5 holders.
- The largest IGM Biosciences buyer in Q2 2021 was Woodline Partners, an estimated $23.3M added.
- The largest IGM Biosciences seller in Q2 2021 was RA Capital Management, an estimated $75.4M sold.
Based on aggregated 13F filings for Q2 2021.